More on ARMP
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $3.20 |
|
|||
| Open | $3.21 | ||||
| 52 Wk High | $2.00 | ||||
| 52 Wk Low | $1.50 | ||||
| Day High | $3.21 | ||||
| Day Low | $2.97 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 5,279 | ||||
- Armata Pharmaceuticals receives two U.S. patents for phage therapies
- Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States
- Form 8-K Armata Pharmaceuticals, For: Sep 23
- Armata gets $3.7M from U.S. DoW for AP-SA02 Phase 3 program
- Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development
- H.C. Wainwright Reiterates Buy Rating on Armata Pharmaceuticals (ARMP)
- Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates
- Form 8-K Armata Pharmaceuticals, For: Sep 14
- FDA grants Armata Pharmaceuticals breakthrough therapy status for AP-SA02
- Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
Entities mentioned with ARMP
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- 13D | View Related Stories »
- Ladenburg Thalmann Financial Services | View Related Stories »
- Show More...
